Precision Neuroscience is a medical technology company developing brain-computer interface (BCI) technology to treat neurological conditions, including movement disorders, epilepsy, and potentially neurodegenerative diseases. The company was founded with the mission of restoring neurological function through advanced neural interface technology.
- Founded: 2022
- Headquarters: New York, New York, USA
- Leadership: Co-founded by Dr. Ben Rapoport (formerly of Neuralink) and others
- Funding: Over $40 million in funding (Series A)
Precision's flagship technology is the Layer 7 Cortical Interface, a minimally invasive brain-computer interface that sits on the surface of the brain (the cortex). Unlike fully implantable electrode arrays that penetrate brain tissue, the Layer 7 interface is designed to be less invasive while still providing high-resolution neural recording.
Key Features:
- Thickness: Ultra-thin film electrode array
- Coverage: Large area coverage of cortical surface
- Resolution: High-density electrode array for detailed neural signal capture
- Safety: Designed to minimize brain tissue disruption
The P7 system is Precision's first clinical-generation BCI platform:
- Neural Recording: Captures electrical signals from cortical neurons
- Stimulation Capability: Can deliver targeted electrical stimulation
- Chronic Monitoring: Designed for long-term implantation
- Data Transmission: Wireless data transmission for real-time monitoring
| Program |
Indication |
Stage |
| Layer 7 Cortical Interface |
Movement disorders |
Early feasibility |
| P7 System |
Epilepsy monitoring |
Preclinical |
| Next-gen platform |
Memory applications |
Discovery |
- FDA Breakthrough Device Designation: Received for certain applications
- Early Feasibility Studies: Initiating first-in-human studies
- Parkinson's Disease: Potential for closed-loop deep brain stimulation optimization
- Essential Tremor: Neural recording to better understand tremor generation
- Dystonia: Monitoring and modulation of abnormal movement patterns
- Seizure Detection: Early identification of seizure onset from neural signals
- Responsive Neurostimulation: Targeted stimulation to interrupt seizures
- Memory Enhancement: Potential applications in Alzheimer's disease
- Stroke Recovery: Neural rehabilitation interfaces
- Brain-Machine Interfaces: Advanced prosthetic control
¶ Competitive Landscape
Precision Neuroscience competes with other BCI companies including:
Precision Neuroscience has raised over $40 million in funding, including a Series A round. The company is backed by investors focused on neurotechnology and medical devices.
¶ Challenges and Considerations
- Long-term Durability: Ensuring device stability over years of implantation
- Signal Decay: Managing signal quality changes over time
- Regulatory Pathway: Novel device class requires extensive clinical validation
- Manufacturing Scale: Scaling production for broader clinical adoption